CJC-1295 / Ipamorelin Blend
Status
No approved product. No FDA-approved labeling exists for either component or for the combination. Neither is an approved medicine in the United States.
What it is
The most common growth hormone secretagogue pairing sold in one vial.
What published research measured
A combination of a growth hormone releasing hormone analogue with a ghrelin receptor agonist. The pharmacological rationale is the most coherent of any blend here and is genuine: the two act through separate receptors on the pituitary, and studies of GHRH analogues given with secretagogues report a growth hormone response greater than either produces alone. That synergy is documented for the mechanism. What is not documented is any outcome. No blend in this category has been studied as a blend. Trial evidence, where it exists, was generated on single agents given alone; no published study of the combination for interaction, additive adverse effects or altered pharmacokinetics was identified in the sources reviewed for this entry. Two practical consequences follow. A multi-compound vial is a compounded preparation, so the stability of each component in the presence of the others, and over the life of the vial, is generally unstudied. If a reaction occurs, multiple components make it difficult to attribute it to one of them, which is one reason clinical pharmacology usually introduces agents one at a time. A further point specific to this pairing: the name CJC-1295 is used commercially for two different molecules — with and without the drug affinity complex that extends half-life from minutes to days — and which one is in a blend materially changes what it does.
Source
Not tied to a single designated source; see the published research on this molecule
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.